Clinical Trial

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

Name: Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC — clinical trial record (NCT07247227)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

This single-arm, multi-center study is to evaluate Sugemalimab plus platinum-based chemotherapy as first-line therapy for patients with locally advanced and metastatic NSCLC in a real-world setting.

Trial Details

NCT Number	NCT07247227
Lead Sponsor	Peking Union Medical College
Conditions	NSCLC
Enrollment	150 participants
Start Date	2023-10-10
Primary Completion	2027-05 (estimated)
Study Completion	2027-05 (estimated)
Updated on ClinicalTrials.gov	2025-11-25